Comprehensive Coronary Artery Disease Care in a Safety-Net Hospital: Results of Get With The Guidelines Quality Improvement Initiative
暂无分享,去创建一个
C. Long | G. Fonarow | P. Mehler | R. Estacio | M. Krantz | W. Baker | Deborah K. Haynes
[1] P. Box. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease , 2006 .
[2] Robert Parrish,et al. Guideline-based standardized care is associated with substantially lower mortality in medicare patients with acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. , 2005, Journal of the American College of Cardiology.
[3] E. Braunwald,et al. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. , 2005, American heart journal.
[4] Jennifer G. Robinson,et al. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. , 2005, The American journal of cardiology.
[5] K. Eagle,et al. Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. , 2004, The American journal of cardiology.
[6] C. Long,et al. Impact of a Cardiac Risk Reduction Program in Vulnerable Patients Hospitalized with Coronary Artery Disease , 2004, Pharmacotherapy.
[7] R. Gliklich,et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. , 2004, Archives of internal medicine.
[8] K. Dickstein,et al. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. , 2004, The American journal of cardiology.
[9] K. Eagle,et al. Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes , 2004, Circulation.
[10] J. LeLorier,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[11] T. Pearson,et al. Bridging the treatment gap: improving compliance with lipid-modifying agents and therapeutic lifestyle changes. , 2003, Preventive cardiology.
[12] P. Gabow,et al. Denver Health: A Model for the Integration of a Public Hospital and Community Health Centers , 2003, Annals of Internal Medicine.
[13] S. Jencks,et al. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. , 2003, JAMA.
[14] R. Stafford,et al. The underutilization of cardiac medications of proven benefit, 1990 to 2002. , 2003, Journal of the American College of Cardiology.
[15] Sankey V. Williams,et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Journal of the American College of Cardiology.
[16] R. Califf,et al. Underuse of aspirin in a referral population with documented coronary artery disease. , 2002, The American journal of cardiology.
[17] Robert Parrish,et al. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002, JAMA.
[18] M. Mccarthy. US heart-guidelines strategy makes promising start , 2001, The Lancet.
[19] R. Califf,et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study , 2001, The Lancet.
[20] A. Gawlinski,et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). , 2001, The American journal of cardiology.
[21] D. Wood,et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries , 2001, The Lancet.
[22] K. Thygesen,et al. Erratum: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction (Journal of the American College of Cardiology (2000) 36 (959-969)) , 2001 .
[23] B. Horne,et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. , 2001, The American journal of cardiology.
[24] J. Tu,et al. Use of the statins in patients after acute myocardial infarction: does evidence change practice? , 2001, Archives of internal medicine.
[25] William Branch,et al. Clinical Inertia , 2001, Annals of Internal Medicine.
[26] J S Alpert,et al. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.
[27] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[28] N. Wenger,et al. Changes in plasma cholesterol levels after hospitalization for acute coronary events. , 1996, Cardiology.
[29] S. Shea,et al. Correlates of nonadherence to hypertension treatment in an inner-city minority population. , 1992, American journal of public health.
[30] M. Cowan,et al. American Heart Association. , 2018, P & T : a peer-reviewed journal for formulary management.